Video
Exciting Results Ignite in Multiple Myeloma and CLL at ASH 2021: Perspectives From Drs Nina Shah and Jacqueline Barrientos
Author(s):
OncLive® speaks with Dr. Nina Shah on some practice-changing multiple myeloma abstracts, and Dr. Jacqueline Barrientos on the latest in chronic lymphocytic leukemia.
Today-
We are reporting from the 2021 ASH Annual Meeting!
We are highlighting some of the top news presented each day during the meeting—and soon we’ll speak with Dr. Nina Shah on some practice-changing multiple myeloma abstracts, and Dr. Jacqueline Barrientos on the latest in chronic lymphocytic leukemia.
Welcome to OncLive News Network! I’m Gina Mauro.
Results from the American Society of Hematology Research Collaborative Data Hub for Hematology Mortality rates in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were higher compared with non-cancer populations who had COVID-19. Additional findings indicated that patients with both active disease and neutropenia at diagnosis were more likely to experience severe COVID-19 infection. However, those with active disease were not found to have increased mortality from the virus.
An observational single-center study suggests that mRNA-1273 SARS CoV-2 vaccination induces a strong antibody response in patients with acute myeloid leukemia and myelodysplastic syndrome.
Tisagenlecleucel produced a high responses in adult patients with relapsed/refractory follicular lymphoma who had received 2 or more prior lines of therapy, according to results from an extended follow-up analysis of patients with at least 12 months of follow-up of the phase 2 ELARA trial The CAR T-cell agent was also linked with durable responses and a promising 12-month progression-free survival rate.
Interim findings from the phase 1/2 LOTIS-3 trial showed that treatment with ibrutinib plus loncastuximab tesirine-lpyl resulted in high objective and complete response rates and an acceptable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.
In multiple myeloma, daratumumab plus talquetamab demonstrated a tolerable safety profile and induced responses in more than 75% of patients with relapsed/refractory disease across dose levels, according to findings from the phase 1b TRIMM-2 study.
Please be sure to check out more of our coverage from the 2021 ASH Annual Meeting at OncLive.com.
That’s all for today. Stay tuned for tomorrow, when Dr. Srdan Verstovsek shares his thoughts on the biggest studies in myeloproliferative neoplasms, and Dr. Naval Daver highlights some exciting data in acute myeloid leukemia.
Thank you for watching OncLive News Network: On Location, I’m Gina Mauro.
